Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated Enterovirus 71 Vaccine (IMBCAMS) is a monovalent, inactivated whole-virus vaccine developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) for the prevention of Hand, Foot, and Mouth Disease (HFMD) caused by Enterovirus 71 (EV71). Produced in Vero cells and adjuvanted with aluminum hydroxide, it was one of the first EV71 vaccines to receive regulatory approval in China. In the context of clinical development for other HFMD vaccines, such as Sinovac Biotech's Inlive, this vaccine has been utilized as an active control (comparator) in Phase 3 and observational follow-up studies to evaluate comparative immunogenicity, safety, and long-term immunity persistence in pediatric populations aged 6 to 71 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Inactivated Enterovirus 71 Vaccine (IMBCAMS).